Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent

This publication has 38 references indexed in Scilit:

• Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
  Hepatology, 2019
• Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes
  Clinics and Research in Hepatology and Gastroenterology, 2019
• ASIC1a promotes high glucose and PDGF-induced hepatic stellate cell activation by inducing autophagy through CaMKKβ/ERK signaling pathway
  Toxicology Letters, 2019
• Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
  Journal of Hepatology, 2016
• Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
  The Lancet, 2016
• Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
  Alimentary Pharmacology & Therapeutics, 2014
• Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
  Cell Metabolism, 2013
• Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
  Diabetologia, 2012
• The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population
  BMC Gastroenterology, 2006
• Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
  Hepatology, 2006